Heparin-induced Thrombocytopenia, Thrombosis
Conditions
Keywords
fondaparinux, thrombosis, heparin-induced thrombocytopenia, pediatrics
Brief summary
This study will evaluate the use of a blood thinner, fondaparinux, which is approved for use in adults (not in children) in a children aged 1-18 years. Subject with a blood clot (thrombosis) or heparin-induced thrombocytopenia who need to be on a blood thinner will be eligible to participate. Subjects will receive a once daily dose of fondaparinux followed by blood tests at 2, 4, 12, and 24 hours after the first dose in order to determine the proper dose for this age group. The hypothesis is that children receiving fondaparinux will be able to receive a once daily dose. The currently available alternative agent, enoxaparin, needs to be given twice daily. In addition, an evaluation of the safety of this medication will be made by assessing for side effects, especially bleeding.
Detailed description
This clinical trial will assess the pharmacokinetics and safety of the novel anticoagulant, fondaparinux sodium (Arixtra) in pediatric patients with thromboembolism. Currently available anticoagulants have significant limitations especially as it applies to the pediatric population. Thus novel agents with improved pharmacologic properties are needed to improve the care of this increasingly recognized complication in children. Furthermore, the only available agent for long-term anticoagulation in children with heparin-induced thrombocytopenia is warfarin. Anticoagulation with warfarin in the pediatric population is problematic due to its narrow therapeutic index and the numerous drug and food interactions necessitating frequent laboratory monitoring. In addition, oral administration of warfarin (which cannot be compounded to a liquid) is difficult in young children. Thus a novel agent for this condition is needed and fondaparinux does not cross-react with heparin antibodies. The aims of the study are to determine the proper dosing regimen (dose and interval) and safety in patients less than 18 years of age with thrombosis or heparin-induced thrombocytopenia. Another aim is to assess the utility of thromboelastography as a monitoring tool for patients on fondaparinux. This will be a pilot study which will have a total of 24 patients in 3 age cohorts with 8 patients per cohort as follows: 1-5 years, 6 -12 years, and 12-18 years as the pharmacokinetics of medications differ by age. Patients will receive an initial dose of 0.1mg/kg subcutaneously daily. After the first dose, fondaparinux levels will be drawn at 2,4,12, and 24 hours after administration. Dose adjustments will be made based on the 4 hour (peak) level and trough levels at 12 and 24 hours will determine if daily dosing is feasible. Thromboelastography will be performed at 2 or 4 hours and 24 hours with the results correlated with the plasma activity level. Safety will be assessed by physical examination, laboratory testing, and if necessary diagnostic imaging to determine the incidence of minor and major bleeding. Pharmacokinetic analyses as well as safety and efficacy determinations will be made which will provide valuable information on this promising new anticoagulant for pediatric patients.
Interventions
DRUGFondaparinux
Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
Sponsors
Children's Hospital Los Angeles
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children between 1 year and 18 years of age. * The presence of documented venous or arterial thrombosis confirmed by diagnostic imaging. * Weight greater than 8.3 kg. * Signed informed consent/assent.
Exclusion criteria
* Patients with active bleeding. * Patients with planned invasive procedures less than 2 weeks from the time of enrollment. * Patients with a contraindication to anticoagulation. * Patients receiving thrombolytic agents. * Patients with an INR\>1.5 or an activated partial thromboplastin time (PTT)\>40 seconds. * Patients with a creatinine level above 1.2 times the upper limit of normal expected for age. * Children \<1 year of age.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Therapeutic Plasma Concentration of Fondaparinux at 21 Days | 21 days | Subjects all had detailed pharmacokinetic measurements done which were subsequently analyzed in a population pharmacokinetic model. This model then informed the dosing recommendations that were published as a result of the study. |
| Number of Abnormal Lab Results Resulting in Adverse Events. | Study period which was up to 21 days of fondaparinux | The primary outcome measure was assessment of safety by reporting the number of abnormal lab results resulting in adverse events. Safety laboratory assessments are as follows: Liver and kidney toxicity will be determined by serial measurements of AST, ALT, total bilirubin, BUN and creatinine. Hematologic toxicity will be assessed by serial CBCs. |
| Bleeding Events | Study period which was up to 21 days of fondaparinux | Bleeding assessment Patients will be monitored for bleeding symptoms by physician and nursing assessment. Major bleeding will be defined as bleeding which is in a critical space (intracranial, retroperitoneal, or visceral) or leads to the need for blood transfusion. Minor bleeding will be all other bleeding and will be classified as clinically significant (i.e. If the physician has to take action to treat the minor bleed) or clinically insignificant (i.e. if the physician does not need to intervene to treat the minor bleed). |
| Adverse Events | Study period which was up to 21 days of fondaparinux | Adverse events will be defined as any untoward or unexpected event which can be a symptom, physical exam sign or laboratory abnormality. Adverse events will be classified as serious if they lead to prolonged hospitalization, re-hospitalization, transfer to an intensive care unit, or death. Adverse events will be categorized in terms of their likely association with fondaparinux as probably related, possibly related, unrelated, or unknown, and will be recorded according to standard adverse reporting guidelines for clinical trials. |
| Thrombocytopenic Events | Study period which was up to 21 days of fondaparinux | Patient's platelet counts should be kept above 50 x 10\^9/L while on study with platelet transfusions as needed with the exception of patients enrolled under the HIT/ suspicion of HIT inclusion (platelet transfusions are contraindicated in HIT). With regards to study patients who experience progressive decreases in platelet count to below 50 x 10\^9/L while receiving fondaparinux (excluding patients being treated for HIT or suspicion of HIT), fondaparinux will be discontinued. |
Countries
United States
Participant flow
Recruitment details
Subjects were recruited between September, 2006 and June, 2009 at 4 sites (Children's Hospital Los Angeles, Children's Hospital of Orange County, Texas Children's Hospital and Nationwide Children's Hospital). All subjects were in the inpatient units of these hospitals for the duration of their study participation.
Pre-assignment details
All recruited subjects entered and completed the study.
Participants by arm
| Arm | Count |
|---|---|
| Fondaparinux Group Single arm group receiving fondaparinux 0.1 mg/kg. | 24 |
| Total | 24 |
Baseline characteristics
| Characteristic | Fondaparinux Group |
|---|---|
| Age, Categorical <=18 years | 24 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Age, Continuous | 12 years STANDARD_DEVIATION 4 |
| Region of Enrollment United States | 24 participants |
| Sex: Female, Male Female | 14 Participants |
| Sex: Female, Male Male | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 24 |
| serious Total, serious adverse events | 0 / 24 |
Outcome results
Primary
Adverse Events
Adverse events will be defined as any untoward or unexpected event which can be a symptom, physical exam sign or laboratory abnormality. Adverse events will be classified as serious if they lead to prolonged hospitalization, re-hospitalization, transfer to an intensive care unit, or death. Adverse events will be categorized in terms of their likely association with fondaparinux as probably related, possibly related, unrelated, or unknown, and will be recorded according to standard adverse reporting guidelines for clinical trials.
Time frame: Study period which was up to 21 days of fondaparinux
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fondaparinux Group | Adverse Events | 0 Adverse Events |
Primary
Bleeding Events
Bleeding assessment Patients will be monitored for bleeding symptoms by physician and nursing assessment. Major bleeding will be defined as bleeding which is in a critical space (intracranial, retroperitoneal, or visceral) or leads to the need for blood transfusion. Minor bleeding will be all other bleeding and will be classified as clinically significant (i.e. If the physician has to take action to treat the minor bleed) or clinically insignificant (i.e. if the physician does not need to intervene to treat the minor bleed).
Time frame: Study period which was up to 21 days of fondaparinux
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fondaparinux Group | Bleeding Events | 2 Adverse Events |
Primary
Number of Abnormal Lab Results Resulting in Adverse Events.
The primary outcome measure was assessment of safety by reporting the number of abnormal lab results resulting in adverse events. Safety laboratory assessments are as follows: Liver and kidney toxicity will be determined by serial measurements of AST, ALT, total bilirubin, BUN and creatinine. Hematologic toxicity will be assessed by serial CBCs.
Time frame: Study period which was up to 21 days of fondaparinux
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fondaparinux Group | Number of Abnormal Lab Results Resulting in Adverse Events. | 0 Adverse Events |
Primary
Therapeutic Plasma Concentration of Fondaparinux at 21 Days
Subjects all had detailed pharmacokinetic measurements done which were subsequently analyzed in a population pharmacokinetic model. This model then informed the dosing recommendations that were published as a result of the study.
Time frame: 21 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fondaparinux Group | Therapeutic Plasma Concentration of Fondaparinux at 21 Days | 24 mg/dL | Standard Deviation 0.001 |
Primary
Thrombocytopenic Events
Patient's platelet counts should be kept above 50 x 10\^9/L while on study with platelet transfusions as needed with the exception of patients enrolled under the HIT/ suspicion of HIT inclusion (platelet transfusions are contraindicated in HIT). With regards to study patients who experience progressive decreases in platelet count to below 50 x 10\^9/L while receiving fondaparinux (excluding patients being treated for HIT or suspicion of HIT), fondaparinux will be discontinued.
Time frame: Study period which was up to 21 days of fondaparinux
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fondaparinux Group | Thrombocytopenic Events | 0 Adverse Events |